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A B S T R A C T
Chronic obstructive pulmonary disease (COPD) and lung cancer are two major diseases of the lung with high rate
of mortality, mostly among tobacco smokers. The glycosylation patterns of various plasma proteins show sig-
nificant changes in COPD and subsequent hypoxia, inflammation and lung cancer, providing promising op-
portunities for screening aberrant glycan structures contribute to early detection of both diseases. Glycoproteins
associated with COPD and lung cancer consist of highly sialylated N-glycans, which play an important role in
inflammation whereby hypoxia leads to accumulation of sialyl Lewis A and X glycans. Although COPD is an
inflammatory disease, it is an independent risk factor for lung cancer. Marked decrease in galactosylation of
plasma immunoglobulin G (IgG) together with increased presence of sialic acids and more complex highly
branched N-glycan structures are characteristic for COPD and lung cancer. Numerous glycan biomarkers have
been discovered, and analysis of glycovariants associated with COPD and lung cancer has been carried out. In
this paper we review fundamental glycosylation changes in COPD and lung cancer glycoproteins, focusing on
IgG to provide an opportunity to distinguish between the two diseases at the glycoprotein level with diagnostic
value.
1. Introduction
Chronic obstructive pulmonary disease (COPD) and lung cancer
(LC) represent a growing global health problem [1]. Both diseases are
primarily associated with cigarette smoking exposure. The prevalence
of COPD in lung cancer cases is 42.4% in smokers compared to 21.8% in
nonsmokers [2]. However, different environmental factors, such as
harmful gases play also important roles in the formation of the diseases
[3,4]. COPD is a progressive deterioration of pulmonary functions,
which can be characterized by airway obstruction and abnormal and
chronic inflammatory responses of the lung to various environmental
effects. [5]. Progression of the disease is associated with the enhanced
chronic inflammation in the airways and the lung caused by various
factors such as inflammatory cytokine release, protease anti-protease
imbalance and autoantibody expression [3,6,7]. Abnormal protein
glycosylation has been widely documented in various inflammatory
diseases, which are accompanied by increased fucosylation and de-
creased galactosylation and sialylation [8,9].
Patients with COPD have a high risk of developing hypoxia and lung
cancer because almost all cancerous tissues show inflammation, thus
the chronic inflammation in COPD might turn to lung cancer by sharing
many common pathways for activation [6,10–13]. Lung cancer is one of
the common malignancies with various histological variants that arise
from different cell types, such as bronchial epithelium, bronchioles,
alveoli, or bronchial mucous glands and the leading cause of cancer-
related deaths worldwide [14,15]. This is a heterogeneous disease
caused by mutations in oncogenes and comprises various subtypes with
pathological and clinical relevance [16]. The most frequent histological
subtypes can be classified as non-small cell lung carcinoma (NSCLC),
which represents 80–85% of all lung cancers. Squamous cell lung
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carcinoma (SCLC) accounts for approximately 20–30% of NSCLC cases,
while adenocarcinomas (ADC) comprise about 40–50% of NSCLC cases
[5,11]. However, neuroendocrine tumors (NET) that arise in neu-
roendocrine cells represent 25% of primary lung cancers [17]. These
subtypes have become important as determinant of therapy in this
disease [18]. Similarly to inflammatory conditions, which are typical
for COPD low galactosylation and sialylation of N-glycans can be ob-
served in lung cancer as well [19,20]. Several fucosylated tetra-an-
tennary structures with varying degrees of sialylation and the level of
outer-arm fucosylation are also increased in inflammatory and malig-
nant lung diseases [21]. Furthermore, fucosylated tri-sialylated tri-an-
tennary glycans show different ratios of sialylation linkages, such as
abundance levels of isomers with two and three α2,3-linked sialic acids
and an increased abundance of an isomer with two α2,6-linked sialic
acids [22].
2. COPD, hypoxia and inflammation
COPD is a progressive disease of the lung during which the risk of
alveolar hypoxia and consequent hypoxemia increases [23]. Hypoxia
develops due to insufficient blood and concomitant oxygen supply of
organs. This condition allows formation of a microenvironment that
essentially contributes to the development of inflammation and ma-
lignant processes. Recently, considerable efforts have been made to
discover the molecular mechanism of hypoxia-induced inflammation in
the lung. It has been found that hypoxia is a potent proinflammatory
stimulus in systemic organs and may cause damaging inflammatory
effects in the lung [24,25]. The extremely low concentration of oxygen
induces inflammatory response, which results in an increase in the
number of immune cells and the activation of downstream signaling
pathways. This process together with regulation of oxygen-dependent
gene expression leads to induction of proinflammatory networks in-
cluding cytokines and chemokines [26]. Hypoxia activates a unique
network of genes in the lung, which does not exist in other organs [27].
The members of the CREB (cyclic AMP response element-binding pro-
tein) transcription family are selectively activated by phosphorylation
under hypoxic conditions. The mechanism of activation is unclear but
CREB phosphorylation may supposedly occur via the AKT kinase
(Protein kinase B) and not the classic G-protein–mediated signal
transduction. AKT kinase is activated in response to a number of cel-
lular signals and CREB phosphorylation may occur directly through the
kinase. However, protein kinase C (PKC) and calcium–calmodulin
complexes may also take part in the activation process [28,29]. Phos-
phorylated CREB activates gene transcription in the nucleus that trig-
gers inflammation.
3. Link between COPD and lung cancer
Increasing number of studies confirmed that there is a link between
COPD and lung cancer [30,31]. 40–70% of lung cancer patients had
been diagnosed with COPD before development of most subtypes of
lung cancer, including ADC, large cell carcinoma (LCC) and particularly
small cell lung carcinoma (SCC) and SCLC [2,32]. However, COPD not
necessarily leads to lung cancer. A comprehensive study conducted in
the United States between 1971 and 1992 indicated that only 6% of
mild and moderate/severe COPD cases led unambiguously to lung
cancer [33]. According to current research, sufficient amount of data is
not available whether each of the subtypes of lung cancer would be
linked to COPD as well as smoking and COPD together necessarily
leading to the development of a specific or uncommon histological
subtype of NSCLC [33–35]. Nevertheless, SCLC has been found to be
most closely related to smoking and COPD since COPD increases the
risk for SCLC histological subtypes by more than fourfold compared to
NSCLC [35]. NSCLC still shows strong correlation with COPD whereby
SCC, LCC and ADC are less associated with the disease. Neuroendocrine
lung tumors are also closely related to COPD, however, the mutual role
of the immune system and the neuroendocrine system in the lower
respiratory tracts of COPD patients is scarcely investigated [36]. The
neuroendocrine immune control at the site of inflammation occurs via
release of neurotransmitters, and various neuropeptides by nerve fibres
[37]. These substances have pro-inflammatory activity, but the ab-
normalities in the neuropeptide pathways in COPD is hardly under-
stood. These observations raise the possibility of common underlying
pathological mechanism(s) in the various histological subtypes of lung
cancer and COPD, which is corroborated by the fact that COPD is a
chronic inflammation and can be a major factor contributing to the
progression of lung cancer [30,32,38,39].
Chronic inflammation associated with COPD likely plays a role in
the pathogenesis of SCLC and acute exacerbation can be the critical
factor in the tumorigenesis of lung cancer. Smoking generates highly
reactive molecules through inflammatory and epithelial cells as well as
leukocytes within the lung leading to formation of superoxide radicals
and hydrogen peroxide. These reactive oxygen species have a key role
in sustaining inflammation in COPD through redox-dependent activa-
tion of inflammatory transcription factors [40,41]. Inflammation may
lead to airway epithelial injury and high cell turnover rates resulting in
accumulation of DNA errors and thus amplification of the carcinogenic
effects of cigarette smoking [42]. Lung epithelium of heavy smokers
finally transforms into a squamous metaplasia phenotype that is asso-
ciated with the severity of airway obstruction [43].
Further, similar abnormalities have been observed in the glycan
structure of various proteins including the members of the im-
munoglobulin G (IgG) family along with the progress of both diseases.
Therefore, accurate and sophisticated molecular diagnostic tools, such
as sensitive detection of changes in the glycan structure of glycoprotein
biomarkers with Liquid Chromatography Mass Spectrometry (LC-MS),
Capillary Electrophoresis Mass Spectrometry (CE-MS) and Capillary
Electrophoresis Laser Induced Fluorescence detection (CE-LIF) could
help in the early diagnosis. Particularly, differentiating biomarkers
could be of great benefit because COPD and lung cancer supposedly
have related pathological background, but require different treatments.
4. Glycoproteins in diseases
Co- and post-translational modifications (PTMs), are enzymatically
controlled processing events, during which various modifying groups
are covalently bound to one or more amino acid residues of the protein
released from the ribosome [44]. The most common ones encompass
glycosylation, phosphorylation, acetylation, methylation, and sulfation
[45]. Most of the human proteins are glycosylated and the glycans play
an important role in cellular differentiation and proliferation, apop-
tosis, oncogenic transformation and metastasis [46–48]. Glycoproteins
generally consist of numerous glycosylated variants (glycoforms) of a
single polypeptide [49]. Although all proteins undergo the same gly-
cosylation processes most glycoproteins develop characteristic glyco-
sylation patterns and thus heterogeneous populations of glycans at each
glycosylation site [49]. Two major types of glycans have been identi-
fied. N-linked glycans have various carbohydrate moieties attached to
the nitrogen atom in the asparagine side chain within a consensus
amino acid sequence of Asn-X-Ser/Thr, where X is not proline. O-linked
glycans contain carbohydrate molecules attached to the oxygen atom of
amino acid residues including serine and threonine. C-linked glycosy-
lation of proteins have also been described [50]. C-mannosylation dif-
fers fundamentally from N- and O-glycosylation, however, the bio-
chemical details of this modification are still unclear [51]. O-
GlcNAcylation (O-GlcNAc) is also a PTM and involves the attachment of
single O-linked N-acetylglucosamine residue to Ser and Thr residues of
cytoplasmic, nuclear and mitochondrial proteins [52,53]. Cycling of O-
GlcNAc is controlled by two enzymes. OGT (O-GlcNAc transferase)
transfers O-GlcNAc to the protein, whereby O-GlcNAcase (OGA) cata-
lyses the hydrolysis of this sugar modification. O-GlcNAcylation reg-
ulates various cellular processes including transcription, translation and
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signal transduction and metabolism [54]. Cancer and many other dis-
eases are associated with aberrant glycosylation patterns of proteins on
both N-linked and O-linked carbohydrate chains that was first described
by Meezan in 1969 and has been confirmed by other scientists [55–59].
Formation of these aberrant structures can be attributed to the changes
in the expression level of glycosyltransferases and glycosidases. One of
the most common changes in the glycan structure in cancer is an in-
crease in the size and branching of N-linked glycans. This increased
branching is often attributed to the increased activity of N-acet-
ylglucosaminyl transferase V (GlcNAc-TV) that leads to β1,6 GlcNAc
branching [60,61]. The increased branching results in formation of
additional sites for terminal sialic acid residues, which together with a
corresponding upregulation of sialyl transferases, leads to an increase in
overall sialylation [62].
Fucosylation occurs by attaching fucose residues to both N and O-
glycans. Its regulation is complicated and involves various fucosyl-
transferases, GDP-fucose (Guanosine 5′-diphospho-β-L-fucose) syn-
thetic enzymes and GDP fucose transporters. Fucosylation can occur in
α1-2, α1-3, α1-4 and α1-6 positions on the oligosaccharides of N and O-
glycans [63]. It has been shown that lack of core fucose on the con-
served (ASN297) oligosaccharide site of human IgG1 enhances anti-
body-dependent cellular cytotoxicity (ADCC), offering an opportunity
for therapy with fucosylated antibodies in various diseases [64]. In-
creased level of core fucosylation has been described in various pa-
thological conditions, such as inflammation and cancer [63]. For in-
stance, stage-dependent changes in IgG fucosylation and an association
of several IgG glycoforms with the survival of cancer suggest that IgG
glycosylation is related to pathogenesis of cancer and progression of the
disease [65].
5. COPD, hypoxia and lung cancer specific glycan biomarkers
Various COPD biomarkers have been discovered, which can be
classified as plasma proteins originally from lungs and inflammation-
related glycoproteins that are associated with some of the features of
the diseases [66,67]. The glycoprotein surfactant protein-D (SP-D) and
the Club (Clara) cell protein 16 (CC-16) are synthesized specifically in
the lung and can be detected in the blood of COPD and healthy patients
[68]. SP-D modulates immune and inflammatory responses in the lung
and plays a role in protecting against viral infection [69]. It is a po-
tential inflammatory biomarker because it is synthetized predominantly
in the respiratory tract [70]. However, the N-glycosylation of SP-D
changes in COPD compared to healthy control and the exacerbation of
the disease generates further alterations in the glycan structure. Mon-
itoring these alterations may help in better understanding of the in-
flammation that influences the glycan structure of proteins in the lung
in the course of the disease.
CC-16, a 16 kD homodimeric protein secreted by bronchiolar club
cells is also a predominant protein in the lung that has shown promise
as a biomarker of disease activity [71]. It protects the respiratory tract
against oxidative stress and inflammation within the airways [72]. CC-
16 expression decreases with lung injury and smoking and is associated
with accelerated decline in lung function [71]. Because of its presumed
relationship to inflammation CC-16 has been proposed as a biomarker
in the study of asthma and bronchial cell dysfunction [73].
Hypoxia accelerates abnormal glycan expression in cancer cells
trough initiating transcription of genes that control glycan synthesis
[74,75]. Enhanced expression of sialyl and fucosyltransferases can be
observed in hypoxia, which contributes to synthesis of abnormal sialyl
Lewis A and sialyl Lewis X glycans [76,77]. Sialic acid residues in these
structures mostly contain N-glycolyl neuraminic acid (Neu5Gc) instead
of N-acetyl neuraminic acid (Neu5Ac) residues, which latter is typical
for normal glycan structures [78]. Some genes; however, are commonly
involved in the synthesis of glycans both in healthy and cancerous cells.
Therefore, hypoxia-induced expression of disialyl Lewis A and sialyl 6-
sulfo Lewis X glycans in normal cells can also be observed. On the other
hand, ischemic conditions in normal cells induce an accumulation of N-
glycolyl disialyl Lewis A and N-glycolyl sialyl 6-sulfo Lewis X glycans.
Although glycans are synthetized by various genes, which reflect ab-
normalities in cancer, genetic aberrations are manifested at the glyco-
protein level. Therefore, a glycoprotein that carries the effects of tumor
hypoxia via abnormal gene expression has a potential to be a useful
biomarker for screening hypoxia induced genes [74].
A comprehensive study of glycan structures of lung tumor tissues of
42 lung adenocarcinoma patients has shown that 29 glycan structures
are differently expressed compared to non-malignant controls [79].
Fig. 1. Glycan structures of human IgG. Core
glycan components: N-acetyl glucosamine,
Mannose. Variable glycan components:
Galactose, N-acetyl glucosamine, Fucose,
Sialic acid. Numbers and Greek letters indicate
the position of a linkage between individual
sugar residues.
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Increased level of two fucosylated, lowly galactosylated tetraantennary
glycans and several oligomannose type glycans together with non- or
lowly galactosylated glycans mostly with core fucosylation were ob-
served. Fully galactosylated glycans, including hybrid type and mostly
without fucose, however, were downregulated in cancerous tissue. In
lung cancer, increase in Sialyl Lewis X (SLeX), monoantennary glycans
and highly sialylated glycans have been observed in the glycan struc-
ture of various proteins, such as the acute phase proteins of haptoglobin
and α-1-Antitrypsin [11,80]. SLeX plays an important role in initiating
inflammation that is characteristic in COPD, thus characterized by the
local inflammatory response in the lungs [81]. α-1-Antitrypsin (A1AT)
is a serum glycoprotein with three potential N-glycosylation sites on
asparagin residues at positions 46, 83 and 247, and shows up-regulated
glycosylation pattern in lung adenocarcinomas [82–84]. A number of
A1AT glycovariants has been observed in lung cancer patients, parti-
cularly showing increase in the N-linked core-fucosylation [85].
6. IgG glycosylation in COPD, hypoxia and lung cancer
Changes in glycan structures associated with various diseases in-
cluding cancer and COPD have been investigated in case of IgG sub-
classes as well. Normally, the biological activity and effector function of
IgGs is modulated by covalently attached bi-antennary N-glycans at the
highly conserved asparagine 297 residue at the CH2 domains of the
crystallizable Fc region on the heavy chain (Fig. 1) [86–93]. The main
N-glycans are core-fucosylated and may carry sialic acid species or
bisecting GlcNAcs [90].
IgG glycans show alternative glycosylation pattern in COPD com-
pared to healthy patients. Pavic et al have completed the first com-
prehensive study of individual variation of plasma protein and IgG N-
glycosylation involving 137 subjects with COPD and 95 matching
controls [66]. They identified 39 peaks for N-glycans in plasma and 24
peaks for N-glycans for purified IgG followed by glycan release with
PNGase F (Peptide N-glycosidase F) and separation with Hydrophilic
Interaction Chromatography - Ultra High Performance Liquid Chro-
matography (HILIC - UHPLC). 16 out of 39 directly measured plasma
glycans (including 4 out of 24 IgG glycans) differed significantly be-
tween the COPD and control groups. They presumed that the total
plasma protein N-glycome reflected an overall trend of glycosylation
changes, which could be attributed to changes in glycosylation of in-
dividual proteins as well as changes in their plasma concentration
leading to enhanced sensitivity to the pathophysiological events.
Complexity of IgG N-glycans exhibit significant decrease in low
branched mono and biantennary species and hypogalactosylation in-
cluding decline in monogalactosylation, which is the most prominent
change of the IgG N-glycome associated with COPD [66,94]. However,
the decrease in galactosylated glycoforms of IgG has been observed in
other autoimmune or inflammatory diseases, therefore it cannot be
considered as a selective biomarker of COPD [95]. On the other hand,
increase in more complex tri- and tetraantennary glycan structures as
well as bisecting GlcNAc (N-acetylglucosamine) on IgG can also be
observed with exacerbation of COPD.
Fig. 2. Preparation of glycoprotein samples for LC-MS. – Intact IgG molecule. – various glycan structures, – iodoacetamide, – affinity ligand. Brown
and orange circles and lines represent other intact and denatured proteins. (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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Hypoxia substantially decreases the levels of N-glycosylation of
various integrins leading to abnormal trafficking to the cell surface
[96]. Regoetzi and coworkers have also confirmed that fucosylation of
IgG is significantly less in hypoxic liver cells (10.4 ± 2.1%) than in
normal cells (20.1 ± 2.2%) but no evidence has been found in relation
to abnormal IgG glycosylation due to hypoxia in COPD or lung cancer
[96,97].
Aberrant glycosylation can be observed in essentially all types of
human cancers [98,99]. Significantly increased level of SLeX, mono-
antennary and trisialylated glycans have been identified in SCLC [100].
Altered branching of N-glycans in conjunction with aberrant glycosy-
lation of mucins have also been observed, which are accompanying
phenomenon of carcinogenesis and cancer metastasis [101–103]. Fur-
ther, Ruhaak and coworkers have found four glycans (Hex3Hex-
NAc4Fuc1, Hex5HexNAc5Sia1, Hex5HexNAc5Sia2, and Hex5Hex-
NAc5Fuc1Sia2), which differed in IgG fractions of lung
adenocarcinoma patients compared to healthy controls [104]. It has
also been revealed that in lung cancer a marked decrease in sera IgG1
Fc - galactosylation occurred together with galactosyl-related Fc-gly-
cosylation, which is not typical for healthy individuals [105].
It is possible that alternative IgG glycosylation might have similar
function(s) with the progress of COPD and lung cancer. This is because
inflammation leads to abnormal N-glycan processing and thus aberrant
glycosylation pattern of proteins can be observed in patients with COPD
[87]. The IgG glycovariants lacking of core fucose have increased af-
finity to activating Fc-receptors (FcγRs) resulting in drastic enhance-
ment of antibody-dependent cellular cytotoxicity, whereby IgG gly-
covariants with terminal sialic acid residue have strong anti-
inflammatory activity [106–108]. However, the link between COPD
and lung cancer considering abnormal IgG glycosylation has been
poorly investigated.
Fig. 3. Mass spectra of trypsinized IgG1-4. Adapted with permission from Hong et al, Absolute quantitation of immunoglobulin G and its glycoforms using multiple
reaction monitoring. Anal. Chem. 2013; 85:8585-8593. Copyright 2013, American Chemical Society [121].
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7. Glycoprotein, glycopeptide and glycan analysis
Mass spectrometry (MS) is a powerful technique for profiling the
human glycome leading to discovery of several potentially promising
biomarkers for several types of diseases [57,109–113]. MS-based
techniques are key for the recent expansion of glycomics capabilities
and they are widely used in glycoprotein analysis. For example, Wu and
co-workers investigated the structure of fucosylated corticosteroid-
binding globulin, histidine-rich glycoprotein, complement factor B, N-
acetylmuramoyl-L-alanine amidase and thyroxine-binding globulin in
ovarian cancer with MS and found significant differences in the glycan
structure of the trypsynized glycoproteins [114,115]. Other authors
have currently reported decreased high-mannose, hybrid-type, com-
plex-type asialo, bi, tri- and tetraantennary sialylated structures in
blood samples of ovarian cancer patients. On the other hand, increased
tri, tetraantennary fucosylated, afucosylated, and fucosylated trian-
tennary structures were observed in MS analysis [84,116].
MS analysis of glycoproteins in most instances requires thorough
sample preparation by exposure the glycoproteins to reducing agents
such as dithiothreitol, which reduce disulfide bonds in the intact pro-
teins, heat denaturation and alkylation with organic compounds, such
as iodoacetamide to prevent re-formation of disulfide bonds in the
denatured protein, and proteolytic digestion, enrichment of the glyco-
peptides, however, losses cannot be avoided (Fig. 2) [117]. Proteolytic
digestion is mostly carried out with trypsin and in combination with
reversed-phase high-performance liquid chromatographic (RP-HPLC)
separation allowing characterization of the proteins of interest and
monitoring for minor alterations in a population of molecules [118].
Recently HILIC is the most frequently applied technique for glycopep-
tide separation and analysis. It employs traditionally polar silica sta-
tionary phases rendered with various hydrophilic organic groups, such
as amino, amide, diol or sulfoalkyl betaine groups and a hydrophobic,
mostly organic mobile phase. Retention increases with the hydro-
philicity of solutes [119]. HILIC can be considered as a variant of
normal-phase liquid chromatography (NP-LC), however, its separation
mechanism is more complicated than that of in NP-LC [120]. HILIC has
numerous advantages over NP-LC or RP-HPLC, for example it is suitable
for analyzing compounds in complex matrices that normally elute in the
dead volume of RP-HPLC. Furthermore, no expensive ion pair reagents
are required in HILIC and it can be conveniently coupled to mass
spectrometry with electrospray ionization (ESI) mode [120].
Hong et al have developed a method using Multiple Reaction
Monitoring (MRM) to monitor protein glycosylation in serum/plasma
to examine quantitative changes in glycosylation at a site-specific level
[121]. They identified 26 glycopeptide fragments from tryptic digested
IgG samples (Fig. 3), which corroborated the findings of other re-
searchers [122]. However, the use of MRM for such a complex glycan
and glycoconjugate analyses is limited, mostly because MRM is per-
formed on triple quadrupole instruments that are often optimized for
small molecules and thus large glycopeptides are outside of the mass
range of the instrument.
Reducing the sample complexity by exposure the glycoprotein or
glycopeptide to glycosidases and the analysis of the glycan structures
themselves may provide a better understanding of glycosylation me-
chanisms in COPD and lung cancer with the opportunity to detect even
more subtle differences in the carbohydrate patterns characteristic of
the two diseases. Increased resolution of separation techniques allows
more sophisticated analysis and identification of the oligosaccharide
structures. Capillary electrophoresis (CE) is a high performance se-
paration technique, which offers high resolution, short analysis time
and minimal consumption of samples making it an attractive technique
for glycoprotein and glycan screening [123]. CE applies a very high
potential (10–30 kV) in a narrow bore (typically 50–100 µm ID) glass
capillary and separation occurs based on the different electrophoretic
mobility of the analytes. The majority of CE instruments are equipped
with UV, LIF detectors or MS. Meszaros and coworkers used CE-LIF to
perform glycoprotein analysis of human serum acquired from healthy,
COPD and patients with comorbidity of COPD lung cancer. They have
identified 13 N-glycan structures and their subclasses, such as fucosy-
lated, mono-, bi-, tri- and tetra-sialylo, as well as mono-, bi-, tri- and
tetra-antennary glycans providing the opportunity for development of
promising biomarkers for early detection of COPD and lung cancer
[124].
Furthermore, some other biomarkers, such as CA-125 (Cancer
Antigen 125), CD44 (Cluster of Differentiation 44, a cell surface ad-
hesion receptor that is highly expressed in many cancers), CD166
(Cluster of Differentiation 166, a transmembrane glycoprotein), lyso-
some-associated membrane glycoprotein 2 (LAMP-2), and pulmonary
surfactant protein A were found to be associated with lung cancer and
tumor progression [125]. Comprehensive glycomic analysis of these
biomarkers may open a new avenue in early diagnosis of lung diseases
and contribute to the discovery of new medicines.
8. Analysis of IgG in COPD and lung cancer
LC-MS is a rapid and sensitive technique for proteomics and
therefore emerged as a unique tool in glycopeptide analysis, for in-
stance investigation of IgG subclasses [111,121,122,126]. Glycopep-
tides are exposed to mass spectrometric analysis followed by proteolytic
cleavage of the IgG molecule and chromatographic separation of the
resulting glycopeptides [127]. Tryptic digestion generates a large
number of glycopeptides with different molecular masses and struc-
tures. Separation and mass spectrometric detection of all IgG
Table 1
Mass spectrometric analysis of trypsinized IgG subclasses. Adapted with per-
mission from Hong Q et al, Absolute quantitation of immunoglobulin G and its
glycoforms using multiple reaction monitoring. Anal. Chem. 2013; 85:8585-
8593. Copyright 2013, American Chemical Society [121].
Compound Name Precursor ion (m/z) Product ion (m/z)
H3N5F1-IgG1 946.5 204.1
H4N4-IgG1 884.1 204.1
H4N4F1-IgG1 932.8 204.1
H3N4F1-IgG1 878.8 204.1
H5N4-IgG1 938.1 366.1
H5N4F1-IgG1 986.8 366.1
H4N5-IgG1 951.7 204.1
H4N5F1-IgG1 1000.5 204.1
H5N5F1-IgG1 1054.5 366.1
H4N4F1S1-IgG1 1029.8 204.1
H5N4F1S1-IgG1 1083.8 366.1
H3N4F1-IgG3/4 873.4 204.1
H4N4F1-IgG3/4 927.4 204.1
H3N5F1-IgG3/4 941.1 204.1
H4N5F1-IgG3/4 995.1 204.1
H5N4F1S1-IgG3/4 1078.4 366.1
H3N5F1-IgG2 935.8 204.1
H4N4F1-IgG2 922.1 204.1
H4N5F1-IgG2 898.9 204.1
H5N4F1-IgG2 976.1 366.1
H3N4F1-IgG2 868.1 204.1
H4N5-IgG2 941.1 204.1
H4N4-IgG2 873.4 204.1
H5N4F1S1-IgG2 1073.1 366.1
H5N5F1-IgG2 1043.8 366.1
H4N4F1S1-IgG2 1019.1 204.1
Peptide IgG1234 (DTLMISR) 418.2 506.3
619.4
Peptide IgG3 472.9 697.4
534.3
Peptide IgG1 839.4 968.5
1067.6
Peptide IgG2 970.1 1100.6
839.5
Peptide IgG4 635.0 1217.6
425.2
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glycopeptides can be performed with the use of modern UPLC tech-
nique with high separation capacity and in conjunction with high re-
solution MS systems, which allows generating large and complex data
sets. However, some characteristic structures of IgG with well-defined
m/z values have been identified (Table 1) contributing to more simple
data review. Typically the characteristic ions with m/z values of 204.1
(HexNAc), 366.1 (Hex1-HexNAc1), 292.09 (Neu5Ac) and 657.24
(Hex1HexNAc1Neu5Ac1) are searched in the mass spectra to identify
glycopeptides followed by tryptic digestion of IgG [121].
Mass spectrometric analysis has revealed abnormal glycosylation of
the IgG family members associated with various diseases, such as
rheumatoid arthritis, inflammatory bowel disease [128], multiple
sclerosis [59], ankylosing spondylitis, primary Sjögren’s syndrome,
psoriatic arthritis [129] and systemic lupus erythematosus (SLE) [95].
In general, the degree of galactosylation is decreased together with
elevated levels of truncated N-glycans in these diseases, just like in lung
cancer [90], however, in rheumatoid arthritis, the lowered degree of
galactosylation is associated with the relative abundance of the bisected
species and it is well expressed in IgG1. Similar tendencies can be ob-
served with the other IgG subclasses (Fig. 4).
IgG glycosylation in COPD and lung cancer with LC-MS is relatively
poorly investigated. Chen and coworkers employed Fourier Transform
Ion Cyclotron Resonance Mass Spectrometery FTICR-MS to evaluate
IgG glycosylation in 259 lung cancer patients. They reported significant
differences in Fc-glycosylation features, such as agalactosylation, ga-
lactosylation, and digalactosylation between lung cancer patients and
healthy controls. A marked increase in IgG1 Fc N-linked-agalactosyla-
tion and decrease in galactosylation and digalactosylation were ob-
served compared to 410 control individuals, which were associated
with increased susceptibility of lung cancer [130].
Fig. 4. HPLC chromatogram of trypsinized IgG and mass spectra of IgG1. C1 and C2: healthy controls, RA1 and RA2: patients with rheumatoid arthritis. With
permission from Wuhrer et al, Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 2007, 7, 4070–4081. Copyright
2007,WILEY-VCH Verlag GmbH & Co. [122].
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9. Conclusion
Abnormal glycosylation patterns of numerous glycoproteins asso-
ciated with different diseases, such as inflammation or cancer have
been discovered and subjected to high sensitivity bioanalytical
screenings. Global glycan analyses has revealed similar glycosylation
patterns of proteins in COPD and lung cancer patients indicating that
the response of cells to inflammation and malignant transformation
processes may occur via similar pathological routes. Generally, de-
crease of the complexity of N-glycans regarding low branched simple
glycans and monogalactosylation is typical in both diseases. On the
other hand, more complex, highly branched tri and tetra antennary
glycans also with sialylation exhibit increase in COPD and lung cancer.
Furthermore, patients diagnosed with lung cancer have increased level
of IgG1 Fc-agalactosylation. Despite of the discovery of these abnormal
IgG glycosylations in COPD and lung cancer, no detailed and compre-
hensive mass spectrometric study of aberrant IgG peptidoglycans has
been provided until now. Therefore, further development of LC-MS and
CE methods is desirable to detect tiny variations in the glycan structures
shedding insight into differences or similarities as well as key points of
IgG glycosylation that might have critical role in formation and con-
sequences of progression of both diseases. UPLC-MS has excellent peak
resolution and detection capabilities to separate the glycopeptide
fragments of trypsinized IgG molecules and could serve as a discovery
tool for new and unknown IgG glycosylation patterns specific to COPD
and lung cancer. CE-MS offers a unique combination of high sensitivity
and resolution as well as minute sample requirement and short analysis
time providing the opportunity for selective diagnosis of the two dis-
eases. Utilization of IgGs as abundant glycan carrying biomarkers can
considerably contribute to better understanding of COPD and lung
cancer on the molecular level.
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